• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

生长中的成骨不全动物模型Col1a2(+/G610C)小鼠的骨矿物质特性。

Bone mineral properties in growing Col1a2(+/G610C) mice, an animal model of osteogenesis imperfecta.

作者信息

Masci Marco, Wang Min, Imbert Laurianne, Barnes Aileen M, Spevak Lyudmila, Lukashova Lyudmila, Huang Yihe, Ma Yan, Marini Joan C, Jacobsen Christina M, Warman Matthew L, Boskey Adele L

机构信息

Weill Cornell Medical College, New York, NY, United States.

Mineralized Tissues Laboratory, Hospital for Special Surgery, New York, NY, United States.

出版信息

Bone. 2016 Jun;87:120-9. doi: 10.1016/j.bone.2016.04.011. Epub 2016 Apr 13.

DOI:10.1016/j.bone.2016.04.011
PMID:27083399
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4862917/
Abstract

The Col1a2(+/G610C) knock-in mouse, models osteogenesis imperfecta in a large old order Amish family (OOA) with type IV OI, caused by a G-to-T transversion at nucleotide 2098, which alters the gly-610 codon in the triple-helical domain of the α2(I) chain of type I collagen. Mineral and matrix properties of the long bones and vertebrae of male Col1a2(+/G610C) and their wild-type controls (Col1a2(+/+)), were characterized to gain insight into the role of α2-chain collagen mutations in mineralization. Additionally, we examined the rescuability of the composition by sclerostin inhibition initiated by crossing Col1a2(+/G610C) with an LRP(+/A214V) high bone mass allele. At age 10-days, vertebrae and tibia showed few alterations by micro-CT or Fourier transform infrared imaging (FTIRI). At 2-months-of-age, Col1a2(+/G610C) tibias had 13% fewer secondary trabeculae than Col1a2(+/+), these were thinner (11%) and more widely spaced (20%) than those of Col1a2(+/+) mice. Vertebrae of Col1a2(+/G610C) mice at 2-months also had lower bone volume fraction (38%), trabecular number (13%), thickness (13%) and connectivity density (32%) compared to Col1(a2+/+). The cortical bone of Col1a2(+/G610C) tibias at 2-months had 3% higher tissue mineral density compared to Col1a2(+/+); Col1a2(+/G610C) vertebrae had lower cortical thickness (29%), bone area (37%) and polar moment of inertia (38%) relative to Col1a2(+/+). FTIRI analysis, which provides information on bone chemical composition at ~7μm-spatial resolution, showed tibias at 10-days did not differ between genotypes. Comparing identical bone types in Col1a2(+/G610C) to Col1a2(+/+) at 2-months-of-age, tibias showed higher mineral-to-matrix ratio in trabeculae (17%) and cortices (31%). and in vertebral cortices (28%). Collagen maturity was 42% higher at 10-days-of-age in Col1a2(+/G610C) vertebral trabeculae and in 2-month tibial cortices (12%), vertebral trabeculae (42%) and vertebral cortices (12%). Higher acid-phosphate substitution was noted in 10-day-old trabecular bone in vertebrae (31%) and in 2-month old trabecular bone in both tibia (31%) and vertebrae (4%). There was also a 16% lower carbonate-to-phosphate ratio in vertebral trabeculae and a correspondingly higher (22%) carbonate-to-phosphate ratio in 2month-old vertebral cortices. At age 3-months-of-age, male femurs with both a Col1a2(+/G610C) allele and a Lrp5 high bone mass allele (Lrp5+/A214V) showed an improvement in bone composition, presenting higher trabecular carbonate-to-phosphate ratio (18%) and lower trabecular and cortical acid-phosphate substitutions (8% and 18%, respectively). Together, these results indicate that mutant collagen α2(I) chain affects both bone quantity and composition, and the usefulness of this model for studies of potential OI therapies such as anti-sclerostin treatments.

摘要

Col1a2(+/G610C)基因敲入小鼠模拟了一个大型老派阿米什家族(OOA)中的IV型成骨不全症,该病症由核苷酸2098处的G到T颠换引起,这改变了I型胶原蛋白α2(I)链三螺旋结构域中的gly-610密码子。对雄性Col1a2(+/G610C)及其野生型对照(Col1a2(+/+))的长骨和椎骨的矿物质和基质特性进行了表征,以深入了解α2链胶原蛋白突变在矿化中的作用。此外,我们通过将Col1a2(+/G610C)与LRP(+/A214V)高骨量等位基因杂交引发的硬化蛋白抑制作用,研究了其对骨成分的挽救能力。在10日龄时,通过微型计算机断层扫描(micro-CT)或傅里叶变换红外成像(FTIRI)观察到椎骨和胫骨几乎没有变化。在2月龄时,Col1a2(+/G610C)胫骨的次级小梁比Col1a2(+/+)少13%,这些小梁比Col1a2(+/+)小鼠的小梁更薄(11%)且间距更宽(20%)。2月龄Col1a2(+/G610C)小鼠的椎骨与Col1(a2+/+)相比,骨体积分数也更低(38%)、小梁数量(13%)、厚度(13%)和连接密度(32%)。2月龄Col1a2(+/G610C)胫骨的皮质骨组织矿物质密度比Col1a2(+/+)高3%;与Col1a2(+/+)相比,Col1a2(+/G610C)椎骨的皮质厚度更低(29%)、骨面积更低(37%)和极惯性矩更低(38%)。FTIRI分析可在约7μm的空间分辨率下提供骨化学成分信息,结果显示10日龄时不同基因型的胫骨之间没有差异。比较2月龄时Col1a2(+/G610C)与Col1a2(+/+)相同类型的骨,胫骨的小梁(17%)、皮质(31%)以及椎骨皮质(28%)中的矿物质与基质比率更高。在10日龄时,Col1a2(+/G610C)椎骨小梁以及2月龄胫骨皮质(12%)、椎骨小梁(42%)和椎骨皮质(12%)中的胶原蛋白成熟度高42%。在10日龄的椎骨小梁(31%)以及2月龄的胫骨(31%)和椎骨(4%)小梁骨中观察到更高的酸性磷酸盐取代。椎骨小梁中的碳酸盐与磷酸盐比率也降低了16%,相应地,2月龄椎骨皮质中的碳酸盐与磷酸盐比率更高(22%)。在3月龄时,同时携带Col1a2(+/G610C)等位基因和Lrp5高骨量等位基因(Lrp5+/A214V)的雄性股骨的骨成分有所改善,呈现出更高的小梁碳酸盐与磷酸盐比率(18%)以及更低的小梁和皮质酸性磷酸盐取代(分别为8%和18%)。总之,这些结果表明突变的胶原蛋白α2(I)链会影响骨量和骨成分,并且该模型对于研究潜在的成骨不全症治疗方法(如抗硬化蛋白治疗)具有实用性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf53/4862917/3a8add3851f4/nihms779845f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf53/4862917/72218764ce9f/nihms779845f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf53/4862917/c1bdab1bd613/nihms779845f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf53/4862917/d4f0326c28f2/nihms779845f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf53/4862917/671a57734c75/nihms779845f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf53/4862917/d26229ad0529/nihms779845f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf53/4862917/3a8add3851f4/nihms779845f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf53/4862917/72218764ce9f/nihms779845f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf53/4862917/c1bdab1bd613/nihms779845f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf53/4862917/d4f0326c28f2/nihms779845f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf53/4862917/671a57734c75/nihms779845f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf53/4862917/d26229ad0529/nihms779845f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf53/4862917/3a8add3851f4/nihms779845f6.jpg

相似文献

1
Bone mineral properties in growing Col1a2(+/G610C) mice, an animal model of osteogenesis imperfecta.生长中的成骨不全动物模型Col1a2(+/G610C)小鼠的骨矿物质特性。
Bone. 2016 Jun;87:120-9. doi: 10.1016/j.bone.2016.04.011. Epub 2016 Apr 13.
2
Combination therapy in the Col1a2 mouse model of Osteogenesis Imperfecta reveals an additive effect of enhancing LRP5 signaling and inhibiting TGFβ signaling on trabecular bone but not on cortical bone.成骨不全症 Col1a2 小鼠模型中的联合治疗揭示了增强 LRP5 信号和抑制 TGFβ 信号对小梁骨的增效作用,但对皮质骨没有作用。
Bone. 2020 Feb;131:115084. doi: 10.1016/j.bone.2019.115084. Epub 2019 Oct 21.
3
Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta.靶向LRP5信号通路可改善成骨不全小鼠模型的骨骼特性。
J Bone Miner Res. 2014 Oct;29(10):2297-306. doi: 10.1002/jbmr.2198.
4
Morphological and mechanical characterization of bone phenotypes in the Amish G610C murine model of osteogenesis imperfecta.Amish G610C 型骨发育不全鼠模型中骨表型的形态学和力学特征。
PLoS One. 2021 Aug 27;16(8):e0255315. doi: 10.1371/journal.pone.0255315. eCollection 2021.
5
Enhanced Wnt signaling improves bone mass and strength, but not brittleness, in the Col1a1(+/mov13) mouse model of type I Osteogenesis Imperfecta.在I型成骨不全的Col1a1(+/mov13)小鼠模型中,增强的Wnt信号传导可改善骨量和骨强度,但不能改善骨脆性。
Bone. 2016 Sep;90:127-32. doi: 10.1016/j.bone.2016.06.005. Epub 2016 Jun 11.
6
The effect of carbamazepine on bone structure and strength in control and osteogenesis imperfecta (Col1a2 ) mice.卡马西平对对照组和骨不全症(Col1a2 )小鼠骨结构和强度的影响。
J Cell Mol Med. 2022 Jul;26(14):4021-4031. doi: 10.1111/jcmm.17437. Epub 2022 Jun 14.
7
Early Fracture Healing is Delayed in the Col1a2 Osteogenesis Imperfecta Murine Model.Col1a2 型成骨不全症小鼠模型中早期骨折愈合延迟。
Calcif Tissue Int. 2018 Dec;103(6):653-662. doi: 10.1007/s00223-018-0461-x. Epub 2018 Aug 3.
8
Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent?成骨不全小鼠模型治疗后成分变化是否存在性别依赖性?
Clin Orthop Relat Res. 2015 Aug;473(8):2587-98. doi: 10.1007/s11999-015-4268-z.
9
Correlations Between Bone Mechanical Properties and Bone Composition Parameters in Mouse Models of Dominant and Recessive Osteogenesis Imperfecta and the Response to Anti-TGF-β Treatment.显性和隐性成骨不全小鼠模型中骨力学性能与骨成分参数的相关性及对抗转化生长因子-β治疗的反应
J Bone Miner Res. 2017 Feb;32(2):347-359. doi: 10.1002/jbmr.2997. Epub 2016 Oct 20.
10
Comparison of bone tissue properties in mouse models with collagenous and non-collagenous genetic mutations using FTIRI.利用傅里叶变换衰减全反射红外光谱法比较具有胶原和非胶原基因突变的小鼠模型的骨组织特性。
Bone. 2012 Nov;51(5):920-8. doi: 10.1016/j.bone.2012.08.110. Epub 2012 Aug 15.

引用本文的文献

1
Nanoscale Structural and Functional Impacts of Disease-Associated Collagen Mutations.疾病相关胶原蛋白突变的纳米级结构和功能影响
bioRxiv. 2025 Sep 4:2025.09.03.673992. doi: 10.1101/2025.09.03.673992.
2
Assessment of submicron bone tissue composition in plastic-embedded samples using optical photothermal infrared (O-PTIR) spectral imaging and machine learning.使用光热红外(O-PTIR)光谱成像和机器学习评估塑料包埋样本中的亚微米骨组织成分
J Struct Biol X. 2024 Oct 9;10:100111. doi: 10.1016/j.yjsbx.2024.100111. eCollection 2024 Dec.
3
Bone Quality and Mineralization and Effects of Treatment in Osteogenesis Imperfecta.

本文引用的文献

1
Effect of anti-sclerostin therapy and osteogenesis imperfecta on tissue-level properties in growing and adult mice while controlling for tissue age.抗硬化蛋白疗法和成骨不全对生长中和成年小鼠组织水平特性的影响,同时控制组织年龄。
Bone. 2016 Mar;84:222-229. doi: 10.1016/j.bone.2016.01.001. Epub 2016 Jan 6.
2
Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap(-/-) Mice, a Model of Recessive Osteogenesis Imperfecta.硬化蛋白抗体治疗改善隐性成骨不全模型Crtap(-/-)小鼠的骨表型。
J Bone Miner Res. 2016 May;31(5):1030-40. doi: 10.1002/jbmr.2776. Epub 2016 Feb 12.
3
Osteogenesis imperfecta.
骨质量和矿化及成骨不全症治疗的影响。
Calcif Tissue Int. 2024 Dec;115(6):777-804. doi: 10.1007/s00223-024-01263-8. Epub 2024 Sep 4.
4
Sclerostin inhibition in rare bone diseases: Molecular understanding and therapeutic perspectives.罕见骨病中骨硬化蛋白抑制:分子认识与治疗前景
J Orthop Translat. 2024 Jun 19;47:39-49. doi: 10.1016/j.jot.2024.05.004. eCollection 2024 Jul.
5
Collagen mutation and age contribute to differential craniofacial phenotypes in mouse models of osteogenesis imperfecta.胶原蛋白突变和年龄导致成骨不全小鼠模型中出现不同的颅面表型。
JBMR Plus. 2024 Jan 4;8(1):ziad004. doi: 10.1093/jbmrpl/ziad004. eCollection 2024 Jan.
6
Combining anabolic loading and raloxifene improves bone quantity and some quality measures in a mouse model of osteogenesis imperfecta.联合应用合成代谢负荷和雷洛昔芬可改善成骨不全症小鼠模型的骨量和部分骨质量指标。
Bone. 2024 Jul;184:117106. doi: 10.1016/j.bone.2024.117106. Epub 2024 Apr 17.
7
Murine Animal Models in Osteogenesis Imperfecta: The Quest for Improving the Quality of Life.成骨不全症的鼠类动物模型:提高生活质量的探索。
Int J Mol Sci. 2022 Dec 22;24(1):184. doi: 10.3390/ijms24010184.
8
An Update on Animal Models of Osteogenesis Imperfecta.成骨不全症动物模型的研究进展。
Calcif Tissue Int. 2022 Oct;111(4):345-366. doi: 10.1007/s00223-022-00998-6. Epub 2022 Jun 29.
9
The effect of carbamazepine on bone structure and strength in control and osteogenesis imperfecta (Col1a2 ) mice.卡马西平对对照组和骨不全症(Col1a2 )小鼠骨结构和强度的影响。
J Cell Mol Med. 2022 Jul;26(14):4021-4031. doi: 10.1111/jcmm.17437. Epub 2022 Jun 14.
10
Dissecting the phenotypic variability of osteogenesis imperfecta.剖析成骨不全症的表型变异性。
Dis Model Mech. 2022 May 1;15(5). doi: 10.1242/dmm.049398. Epub 2022 May 16.
成骨不全症
Lancet. 2016 Apr 16;387(10028):1657-71. doi: 10.1016/S0140-6736(15)00728-X. Epub 2015 Nov 3.
4
Evidence of altered matrix composition in iliac crest biopsies from patients with idiopathic juvenile osteoporosis.特发性青少年骨质疏松症患者髂嵴活检中基质成分改变的证据。
Connect Tissue Res. 2016;57(1):28-37. doi: 10.3109/03008207.2015.1088531. Epub 2015 Nov 5.
5
Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent?成骨不全小鼠模型治疗后成分变化是否存在性别依赖性?
Clin Orthop Relat Res. 2015 Aug;473(8):2587-98. doi: 10.1007/s11999-015-4268-z.
6
Hindlimb Skeletal Muscle Function and Skeletal Quality and Strength in +/G610C Mice With and Without Weight-Bearing Exercise.有或无负重运动的+/G610C小鼠的后肢骨骼肌功能、骨骼质量和强度
J Bone Miner Res. 2015 Oct;30(10):1874-86. doi: 10.1002/jbmr.2518. Epub 2015 May 14.
7
Energetic basis for the molecular-scale organization of bone.骨骼分子尺度组织的能量基础。
Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):326-31. doi: 10.1073/pnas.1404481112. Epub 2014 Dec 24.
8
Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment.快速生长的成骨不全Brtl/+小鼠模型通过使用硬化蛋白抗体治疗可改善骨量和骨强度。
Bone. 2015 Feb;71:115-23. doi: 10.1016/j.bone.2014.10.012. Epub 2014 Oct 23.
9
Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta.硬化蛋白抗体治疗在严重成骨不全小鼠模型中的作用。
Bone. 2014 Sep;66:182-8. doi: 10.1016/j.bone.2014.06.015. Epub 2014 Jun 19.
10
Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength.成骨不全症的成年Brtl/+小鼠模型显示出对硬化蛋白抗体治疗的合成代谢反应,骨量和骨强度增加。
Osteoporos Int. 2014 Aug;25(8):2097-107. doi: 10.1007/s00198-014-2737-y. Epub 2014 May 7.